In vivo application of hpCas13d in two mouse models successfully suppressed the altered alleles linked to hypertrophic cardiomyopathy.
Treatment with hpCas13d prevented cardiac hypertrophy in these models.
Simplified
BACKGROUND: Familial has severe clinical complications of heart failure, arrhythmia, and sudden cardiac death. Heterozygous single nucleotide variants (SNVs) of sarcomere genes such asare the leading cause of this type of disease. CRISPR-Cas13 (clustered regularly interspaced short palindromic repeats and their associated protein 13) is an emerging gene therapy approach for treating genetic disorders, but its therapeutic potential in genetic cardiomyopathy remains unexplored. MYH7
METHODS: We developed a sensitive allelic point mutation reporter system to screen the mutagenic variants of Cas13d. On the basis of Cas13d homology structure, we rationally designed a series of Cas13d variants and obtained a high-precision Cas13d variant (hpCas13d) that specifically cleaves thevariant RNAs containing 1 allelic SNV. We validated the high precision and low collateral cleavage activity of hpCas13d through various in vitro assays. We generated 2 HCM mouse models bearing distinctSNVs and used adenovirus-associated virus serotype 9 to deliver hpCas13d specifically to the cardiomyocytes. We performed a large-scale library screening to assess the potency of hpCas13d in resolving 45 humanallelic pathogenic SNVs. MYH7MYH7MYH7
RESULTS: Wild-type Cas13d cannot distinguish and specifically cleave the heterozygousallele with SNV. hpCas13d, with 3 amino acid substitutions, had minimized collateral RNase activity and was able to resolve various humanpathological sequence variations that cause hypertrophic cardiomyopathy. In vivo application of hpCas13d to 2 hypertrophic cardiomyopathy models caused by distinct humananalogous sequence variations specifically suppressed the altered allele and prevented cardiac hypertrophy. MYH7MYH7MYH7
CONCLUSIONS: Our study unveils the great potential of CRISPR-Cas nucleases with high precision in treating inheritable cardiomyopathy and opens a new avenue for therapeutic management of inherited cardiac diseases.
Key numbers
71.57%
Discrimination Ratio Increase
Discrimination ratio of hpCas13d for human pathogenic SNVs.
76.8±3.3%
Cardiac Function Improvement
Ejection fraction in hpCas13d-treated mice vs. untreated controls.
0.64±0.02 mm
Left Ventricular Thickness Reduction
Left ventricular thickness in hpCas13d-treated mice vs. untreated controls.
Full Text
We can’t show the full text here under this license.